Effects of magnesium sulfate and labetalol combined therapy on blood pressure and pregnancy outcomes in early-onset severe preeclampsia

Objective: To observe the efficacy of magnesium sulfate and labetalol combined therapy in early-onset severe preeclampsia. Methods: One hundred and twenty cases of pregnant women with early-onset severe preeclampsia admitted to our hospital from January 2010 to December 2014 were included in this study. The subjects were randomly divided into two groups: the study group and the control group. The study group was treated with magnesium sulfate and labetalol, while the control group was treated with magnesium sulfate and nifedipine. The two groups were compared in terms of changes in systolic pressure/diastolic blood pressure at 1 hr and 4 hrs after medical treatment, respectively; gestational age at delivery gestational age at delivery, modes of delivery and neonatal Apgar scores respectively; and the changes inurinary protein concentrations and the serum creatinine levels, the pregnancy outcomes of the two groups were also observed. Results: One hour after treatment, the systolic blood pressure in the study group decreased significantly compared with that of the control group, with a statistically significant difference (P<0.05); four hours after treatment, both the systolic and diastolic blood pressure of the two groups decreased significantly (the study group decreased more significantly), and the differences were statistically significant (P<0.05); the differences were statistically significant in gestational age at delivery gestational age at delivery and neonatal Apgar scores between the two groups (P<0.05). After treatment, urinary protein concentration and serum creatinine levels were significantly lower in the study group than in the control group (P<0.05) and the incidence of adverse pregnancy outcomes in the study group was also obviously lower than that of the control group (P<0.05). Conclusion: The labetalol and magnesium sulfate combined therapy was effective for lowering the blood pressure of patients with early-onset severe preeclampsia and can improve their pregnancy outcomes, so the regimen would be of significance in clinical practice.